Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based ...
“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...
Dyne Therapeutics is a clinical-stage biotechnology company focusing on treatments ... SRPT's drug was initially approved in ...
The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.
About $1.6 billion has been invested in research that has yielded little progress, disappointing many who suffer with the ...
The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...
Zacks Small Cap Research on MSN20h
DWTX: Phase 2 Long COVID Results Expected SoonDWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.
Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...
However, Neurocrine has a pipeline of muscarinic assets closely behind NBI-568, three of which are in phase 1 and all three ...
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Compass Therapeutics (CMPX – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback